AST-05X / Aston Sci., Korea Research Institute of Chemical Technology - LARVOL DELTA

AST-05X: A novel GCN2 inhibitor as a promising anti-cancer approach for sarcoma (AACR 2024) - "In addition, based on the results of ISR-related gene expression profiling GEP analysis, we identified potential CDx biomarkers for evaluating the diagnosis and treatment response of sarcoma.Conclusion This study is currently investigating the efficacy of the drug in sarcoma patient-derived xenograft models. AST-05X is a GCN2 inhibitor that has the potential to validate the inhibition of GCN2 as a promising anti-cancer approach for sarcoma, a rare cancer with limited therapeutic alternatives."

Oncology • Sarcoma • Solid Tumor • ATF4 • EIF2A • EIF2S1

Aston Science attends the American Association for Cancer Research… Announcement of results from a total of 6 studies, including cancer treatment vaccine [Google translation] (MedigateNews) - "Additionally, Aston Science presented at this academic conference: immunogenicity preclinical results of AST-11X, a vaccine using KRAS non-mutated class II epitope; AST-301 (HER2 vaccine, clinical trial in gastric cancer) Preclinical results of antitumor effect for combination therapy with HER2 ADC (Phase 2 drug); Preclinical results for antitumor effect for combination therapy with AST-201 (IGFBP2 vaccine, phase 2 clinical drug) and Keytruda in ovarian cancer; Advanced solid cancer A total of six preclinical results, including the preclinical results of AST-05X, a targeted treatment targeting ISR (integrated stress response) inhibition, are scheduled to be disclosed through poster presentations."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor